secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUCELL CORP /DE/ (ICCC)
CIK:        0000811641
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001213900-23-001673
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuCell reports Q4 2022 preliminary sales down 28% YoY; full year down 3.5%
----------------------------------------------------------------------------

- Q4 2022 sales $3.91M vs $5.44M in Q4 2021, a decline of 28.2%.
- FY2022 sales $18.57M vs $19.24M in FY2021, down 3.5%.
- Backlog $2.5M as of Dec 31, 2022, up from $205k at Sep 30, 2022, similar to $2.4M a year ago.
- Production equipment delays and Q3 contamination events prolonged backlog and reduced output.
- Expects to submit Re-Tain CMC Technical Section to FDA in Q1 2023 with 6-month review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/0001213900-23-001673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/811641/000121390023001673/ea171435-8k_immucell.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-001673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer